Literature DB >> 11880366

Delineation of the key amino acids involved in neutrophil inhibitory factor binding to the I-domain supports a mosaic model for the capacity of integrin alphaMbeta 2 to recognize multiple ligands.

Valentin A Ustinov1, Edward F Plow.   

Abstract

To gain insight into the mechanism by which the alpha(M)I-domain of integrin alpha(M)beta(2) interacts with multiple and unrelated ligands, the identity of the neutrophil inhibitory factor (NIF) recognition site was sought. A systematic strategy in which individual amino acid residues within three previously implicated segments were changed to those in the alpha(L)I-domain, which is structurally very similar but does not bind NIF, was implemented. The capacity of the resulting mutants, expressed as glutathione S-transferase fusion proteins, to recognize NIF was assessed. These analyses ultimately identified Asp(149), Arg(151), Gly(207), Tyr(252), and Glu(258) as critical for NIF binding. Cation binding, a function of the metal ion-dependent adhesion site (MIDAS) motif, was assessed by terbium luminescence to evaluate conformational perturbations induced by the mutations. All five mutants bound terbium with unaltered affinities. When the five residues were inserted into the alpha(L)I-domain, the chimera bound NIF with high affinity. Another ligand of alpha(M)beta(2), C3bi, which is known to use the same segments of the alpha(M)I-domain in engaging the receptor, failed to bind to the chimeric alpha(L)I-domain. Thus, the alpha(M)I-domain appears to present a mosaic of exposed amino acids within surface loops on its MIDAS face, and different ligands interact with different residues to attain high affinity binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880366     DOI: 10.1074/jbc.M110242200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Opening the field of integrin biology to "biased agonism".

Authors:  Daniel I Simon
Journal:  Circ Res       Date:  2011-11-11       Impact factor: 17.367

2.  Inhibition of integrin αDβ2-mediated macrophage adhesion to end product of docosahexaenoic acid (DHA) oxidation prevents macrophage accumulation during inflammation.

Authors:  Kui Cui; Nataly P Podolnikova; William Bailey; Eric Szmuc; Eugene A Podrez; Tatiana V Byzova; Valentin P Yakubenko
Journal:  J Biol Chem       Date:  2019-08-08       Impact factor: 5.157

3.  Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice.

Authors:  Dennis Wolf; Jan-David Hohmann; Ansgar Wiedemann; Kamila Bledzka; Hermann Blankenbach; Timoteo Marchini; Katharina Gutte; Katharina Zeschky; Nicole Bassler; Natalie Hoppe; Alexandra Ortiz Rodriguez; Nadine Herr; Ingo Hilgendorf; Peter Stachon; Florian Willecke; Daniel Duerschmied; Constantin von zur Muhlen; Dmitry A Soloviev; Li Zhang; Christoph Bode; Edward F Plow; Peter Libby; Karlheinz Peter; Andreas Zirlik
Journal:  Circ Res       Date:  2011-10-13       Impact factor: 17.367

4.  Antagonism of CD11b with neutrophil inhibitory factor (NIF) inhibits vascular lesions in diabetic retinopathy.

Authors:  Alexander A Veenstra; Jie Tang; Timothy S Kern
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

5.  Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbα.

Authors:  Yunmei Wang; Huiyun Gao; Can Shi; Paul W Erhardt; Alexander Pavlovsky; Dmitry A Soloviev; Kamila Bledzka; Valentin Ustinov; Liang Zhu; Jun Qin; Adam D Munday; Jose Lopez; Edward Plow; Daniel I Simon
Journal:  Nat Commun       Date:  2017-05-30       Impact factor: 14.919

Review 6.  Structural Immunology of Complement Receptors 3 and 4.

Authors:  Thomas Vorup-Jensen; Rasmus Kjeldsen Jensen
Journal:  Front Immunol       Date:  2018-11-26       Impact factor: 7.561

7.  Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha.

Authors:  Raila Ehlers; Valentin Ustinov; Zhiping Chen; Xiaobin Zhang; Ravi Rao; F William Luscinskas; Jose Lopez; Edward Plow; Daniel I Simon
Journal:  J Exp Med       Date:  2003-10-06       Impact factor: 14.307

8.  A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction.

Authors:  Patrick M Siegel; István Bojti; Karlheinz Peter; Philipp Diehl; Nicole Bassler; Jessica Holien; Ulrike Flierl; Xiaowei Wang; Philipp Waggershauser; Xavier Tonnar; Christopher Vedecnik; Constanze Lamprecht; Ivana Stankova; Tian Li; Thomas Helbing; Dennis Wolf; Nathaly Anto-Michel; Lucia Sol Mitre; Julia Ehrlich; Lukas Orlean; Ileana Bender; Anne Przewosnik; Maximilian Mauler; Laura Hollederer; Martin Moser; Christoph Bode; Michael W Parker
Journal:  Basic Res Cardiol       Date:  2021-03-15       Impact factor: 17.165

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.